According to Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions, there are several ways that employers can alleviate the impacts of co-pay accumulator adjustment programs on their employees, including by increasing awareness of the programs, expanding preventive drug lists, subsidizing benefits for low-income workers, and considering the true financial impact of these programs.
According to Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions, there are several ways that employers can alleviate the impacts of co-pay accumulator adjustment programs on their employees, including by increasing awareness of the programs, expanding preventive drug lists, subsidizing benefits for low-income workers, and considering the true financial impact of these programs.
Transcript
Are there suggestions for how to adjust these co-pay accumulator adjustment programs to address some of the unintended consequences?
Sure, there are a number of ways that employers, plan sponsors can perhaps think differently about the use of the co-pay accumulator cards. And I think, first and foremost, one has to think about, what’s the goal that one is trying to achieve with the co-pay accumulator cards and is it really financially impactful for the employer. So that’s really the first issue, and our preliminary research would indicate that, based on modeling, this literally translates to about a penny per member per month in terms of additional cost for the employer if they allow those co-pay cards to be used without a co-pay accumulator program.
But in terms of modifying the co-pay accumulator adjustment programs, there are a number of factors that could be considered. One is foundationally, if an individual is on specialty drugs, they probably should be counseled or at least be made aware of the existence of the co-pay accumulator adjustment programs at the time of benefits enrollment so that they can choose perhaps to enroll in a PPO [preferred provider organization] plan or non—high-deductible health plan that would protect them to some degree from that unanticipated high payment when the co-pay support runs out. So that’s number 1 at the foundational level.
There are a number of modifications that could be implemented with respect to application of the co-pay accumulator adjustment programs, probably the most important is which medications are included in that co-pay accumulator adjustment program. Not all medications are; for example, in the study that we performed looking at this issue, medications for multiple sclerosis were on the preventive drug list and excluded from the eligibility for the co-pay accumulator adjustment program. So, employers have an opportunity to include more medications on that preventive drug list and be selective about which medications are subject to the co-pay accumulator program or not.
The other issue from an affordability standpoint is to ensure that individuals who are perhaps low-income workers may have an opportunity to have their benefit design subsidized to make the benefits more equitable for them, such that they can afford to pay the cost of the deductible should they choose that plan. That kind of subsidy support can be provided in the form of premium reductions for the plan design, [or] it can be in the form of wage-based deductible levels or wage-based employer contributions to the HSA [health savings account].
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More